Abstract
Cancer is the leading cause of morbidity and mortality worldwide. So many researches have been studied to overcome the disease. We have studied sonodynamic therapy (SDT). Our SDT is based on cellcidal effects of reactive oxygen species that are produced by the interaction between drug delivery system (DDS) and high intensified focused ultrasound (HIFU). A pharmaceutical company now investigates the DDS in a human clinical trial for conventional chemotherapy. The efficacy of the SDT has been demonstrated in a mouse model, and has been expected to realize a novel cancer therapy that is excellent in low invasiveness and little side effects, because the treatment will be provided by applying a combination of a low-energy HIFU and a minute quantity injection of DDS (1/6 dose injection compared with conventional chemotherapy). A clinical trial of the SDT has been projected in collaboration with medical devise companies (HIFU), pharmaceutical companies (DDS). We have started a discussion with PMDA (Pharmaceutical and Medical Devise Agency, Japanese regulatory agency).
